STAT1 serves as an important regulator in the response to pathogens, oncogenic transformation, and genotoxic insults. It exerts these effects by shaping the innate and adaptive immune response and by participating in genotoxic stress pathways, leading to apoptosis and inhibition of cell proliferation. We have investigated the role of STAT1 in hematopoietic toxicity induced by doxorubicin in STAT1-proficient and -deficient mice. Whereas the early genotoxic effect of doxorubicin did not depend on STAT1, expression of STAT1 was required for efficient B lymphocyte repopulation in the recovery phase. We found a lower abundance of lymphocyte precursors in the BM of STAT1-deficient animals, which was particularly evident after doxorubicin-induced hematopoietic toxicity. In accordance, colony-forming assays with STAT1-deficient BM cells revealed a decreased number of pre-B colonies. Differentiation from the pro-B to the pre-B stage was not affected, as demonstrated by unaltered differentiation of purified B cell precursors from BM in the presence of IL-7. With the exception of Sca-1, expression of genes implicated in early lymphocyte development in pro-B cells did not depend on STAT1. Our findings indicate a specific requirement for STAT1 in lymphoid development before differentiation to pre-B cells, which becomes particularly apparent in the recovery phase from doxorubicin-induced hematopoietic toxicity. J. Leukoc. Biol. 95: 000 -000; 2014.
Introduction
STAT1 serves as a key protein to orchestrate the defense against insults to the organism, such as infection by pathogens [1] , oncogenic transformation [2] , or genotoxic agents [3, 4] . By regulating transcription of type I and type II IFNinduced genes [5] implicated in an innate antiviral response, in effector functions of NK cells and macrophages, as well as in antigen processing and Ig isotype switching, STAT1 has a nonredundant function in shaping the innate and adaptive immune response to pathogens. As a consequence, impaired clearance of pathogens, in particular, mycobacterial infections and to a lesser extent, viral infections, is observed in STAT1-deficient children [6] , as well as in mice with targeted deletion of STAT1 [7, 8] .
The antioncogenic function of STAT1 has been attributed to its role in tumor immunosurveillance [2] , as well as to a tumor cell-intrinsic, protective function against transformation [9] . The latter effect might be related to STAT1-mediated regulation of the expression of proapoptotic proteins, such as Fas ligand, caspases, and to promotion of cell-cycle arrest via induction of p21 [10] . Contradictory results have been described regarding the role of STAT1 in the response to chemotherapeutic agents. STAT1 has been proposed to facilitate the growth arrest and elimination of cells with damaged DNA by interaction with p53 [4] and its par-ticipation in the ATM pathway [11] , and this might explain the synergy between STAT1 and chemotherapeutic agents observed in cancer cell lines [3] . On the other hand, overexpression of STAT1 was found to be associated with resistance to chemotherapy [12, 13] . As a possible mechanism to explain this phenomenon, an adaptation process with selection for tumor clones, with an aggressive phenotype and resistance to genotoxic stress, has been proposed to occur [14] .
The anthracyline DNA-damaging agent doxorubicin serves as a chemotherapeutic drug in the treatment of various forms of cancer [15] . As a DNA intercalator, it stabilizes the complex between DNA and topoisomerase II, thereby leading to an accumulation of DNA double-strand breaks, inhibition of cellcycle progression in S-phase, activation of genotoxic stress pathways, and induction of tumor cell apoptosis. A common side-effect of doxorubicin-based therapy is BM toxicity, resulting in reversible suppression of hematopoiesis. As previous reports described a synergistic interaction between doxorubicin and STAT1 in promoting cell-cycle arrest and apoptosis of tumor cells [3] , we were interested in whether a similar interaction is also involved in promoting BM toxicity of doxorubicin. We therefore examined the hematopoietic compartment of STAT1-proficient and -deficient mice for its sensitivity to doxorubicin treatment. The experiments did not support the hypothesis of a requirement for STAT1 in enhancing the toxic effect of this drug on the BM. Instead, an unexpected, protective role of STAT1 in the recovery phase from the toxic effect of doxorubicin was observed. Investigations on the underlying mechanism of this phenonenon revealed an impaired expansion of early hematopoietic precursors in STAT1-deficient mice with a specific impact on the developing B lymphocytes in the BM under steady-state and treatment conditions. Whereas this defect affected the pool of mature B lymphocytes only slightly in the periphery under steady-state conditions with lower demands of supply of BM-derived lymphoid precursors, it became apparent in the recovery phase from doxorubicin-induced BM suppression, characterized by an increased requirement for regeneration of B cells. [7] , generated in the C57BL/6 background, were kindly provided by Thomas Decker University of Vienna, Austria. Genotyping was performed as described in Supplemental materials. Doxorubicin (2 mg/ml; Ebewe Pharma, Unterach, Austria) was injected into 5-to 6-week-old mice i.p. at a dose of 10 or 15 mg/kg body weight, and mice were monitored for a period of up to 30 days after injection. Fig. 1 . Total cellularity of thymus as well as the total cell number of the indicated major lymphocyte populations in thymus and in BM of two femurs were determined for WT and KO mice with five to 10 mice/group and are shown as mean Ϯ sem. Significant differences between WT and KO mice, as evaluated by Student's ttest, are indicated by asterisks. 
MATERIALS AND METHODS

Mice
Immunofluorescence and image processing
Spleens were frozen in Tissue-Tek O.C.T. embedding medium (Sakura, Staufen, Germany) and stored at Ϫ70°C until further processing. Stainings were performed on 7 m-thick slices, fixed in aceton. Primary antibodies used were anti-CD3 conjugated with Alexa 488 (Clone 17A2, 1:200; BioLegend) and biotinylated anti-CD19 (Clone 6D5, 1:200; BioLegend). As secondary reagent, Streptavidin-PE (1:400; BioLegend), was used. The stainings were visualized with an Olympus BX50 microscope equipped with a charge-coupled device camera (Princeton Instruments, Planegg, Germany). The images were contrast-enhanced and thresholded and the CD19-positive area/field calculated with ImageJ software (U.S. National Institutes of Health, Bethesda, MD, USA).
Colony-forming assay
A mouse colony-forming cell assay was performed with 2 ϫ 10 5 BM cells or 3 ϫ 10 4 sorted pro-B cells (CD43
) for pre-B colonies and with 2 ϫ 10 4 BM cells for myelocyte colonies that were seeded in 1 ml methylcellulose medium (StemCell Technologies). For pre-B colonies, MethoCult 3630 (1% methylcellulose, 30% FBS, 2 mM L-glutamine, ␤-ME, and 10 ng/ml mIL-7) and for myelocyte colonies, MethoCult 3234 (1% methylcellulose, 15% FBS, 1% BSA, 10 g/ml insulin, 200 g/ml transferrin, 2 mM L-glutamine, and ␤-ME), supplemented with 50 ng/ml mG-CSF, 10 ng/ml mIL-3, and 10 ng/ml mIL-6 (PeproTech, London, UK), were used. After 7 days in culture, colonies were counted under light microscopy.
In vitro differentiation of B lymphocytes
For the in vitro differentiation of B-lymphocytes from their precursors in the BM, 2.5 ϫ 10 6 whole BM cells or 1 ϫ 10 6 B220 sorted cells were cultured in lymphocyte medium, supplemented with 25 ng/ml mIL-7 for up to 6 days. Lymphocyte medium contains RPMI 1640, 10 mM HEPES, 50 M ␤-ME, 10% FBS, 1 mM pyruvate, 100 U/ml penicillin G, 100 g/ml streptomycin sulfate, and 50 M gentamycin. 
BM transplantation
In vitro proliferation assay
Proliferation assay was performed by BrdU incorporation or dilution of CFSE dye. For BrdU incorporation assay, 2.5 ϫ 10 6 BM cells from STAT1 WT or KO mice were cultured in lymphocyte medium without or with 50 ng/ml mIL-7 (PeproTech) for 38 h. BrdU (10 M) was added for the final 3 h. Labeled cells were stained with anti-B220, followed by intracellular BrdU staining using the FITC BrdU flow kit (BD PharMingen, San Diego, CA, USA), according to the manufacturer's instructions. For the CFSE assay, 1.5 ϫ 10 6 B220-sorted cells were labeled with 5 M CFSE (Sigma-Aldrich, St. Louis, MO, USA), followed by culture in lymphocyte medium, supplemented with 25 ng/ml mIL-7 for 3 days.
Spectratyping of immature B cells from the BM
IgM ϩ
IgD
Ϫ cells from the BM were FACS-sorted and the size differences in the repertoire of V H -DJ H gene rearrangements analyzed after amplification with two rounds of PCR, essentially as described [16] . In the first round, primers specific for the J558 V H region gene, together with a primer specific for the C constant region, and cDNA from the sorted cells were used. In the second run-off round, 1 l first-round PCR product was used as a template and labeled with V H J558 forward and 5= FAM-labeled C reverse primers. Subsequently, product length was analyzed by capillary electrophoresis. Sequences of primers are: V H 1_F, aaggccacactgactgtagac; C_R, tggccaccagattcttatcag; and C_FAM_R, agacgagggggaagacatttg; and PCR conditions: first-round reaction, 95°C for 2 min; 95°C for 1 min, 60°C for 1 min, and 72°C for 1 min, repeated for 34 cycles; and 72°C for 5 min; and second-round reaction, 95°C for 2 min; 95°C for 1 min, 60°C for 1 min, and 72°C for 1 min, repeated for 10 cycles; and 72°C for 5 min.
RNA isolation and real-time PCR
RNA isolation from cultured BM cells and cDNA preparation by RT were done as described [17] . Amplification of SOCS1, SOCS2, SOCS3, CIS, IRF-1, and CXCL10 genes was performed with the TaqMan methodology, as described [17] . Amplification of TBP, IRF-8, EBF1, Pax5, Sca-1, cKit, Ikaros, Aiolos, PU.1, BCL6, and Mx1 genes was done as described [18] . PCR conditions for EvaGreen mix were as follows: 95°C for 3 min, 40 cycles of 95°C for 10 s, 60°C for 15 s, and 72°C for 20 s, with a following acquisition of melting curve data. For both methods, amplification of TBP was used as a control. Relative mRNA expression levels were calculated as relative amount of specific cDNA versus TBP, using the ⌬Ct method (2
Ϫ⌬Ct
) or the ⌬⌬Ct method (2 Ϫ⌬⌬Ct ), where ⌬Ct was defined as Ct (gene) Ϫ Ct (TBP) and ⌬⌬Ct as ⌬Ct Ϫ ⌬Ct (WT control). Primers and probe sequences are shown in Supplemental materials.
Western blotting
Whole-cell lysates were prepared as described [19] . Protein concentration was measured by the Bradford method, and equal amounts of protein were loaded on SDS-PAGE gels. Immunoblotting was performed with mouse antibodies against STAT1␣ p91 
Statistical analysis
The Student's t-test was used to assess the significance of differences between mean values. A two-way ANOVA with Bonferroni post hoc test was used (see Figs. 5 and 8). Levels of significance for t-test and Bonferroni post hoc test are indicated as *P Ͻ 0.05; **P Ͻ 0.01; and ***P Ͻ 0.001. The statistical analysis was performed with GraphPad Prism (GraphPad Software, La Jolla, CA, USA).
Supplemental materials
Online Supplemental materials contain sequence of primers used for RT-PCR and genotyping.
RESULTS
Impaired restoration of the B cell compartment after doxorubicin induced hematopoietic toxicity in STAT1-deficient mice
The sensitivity of STAT1-proficient and -deficient mice to BM toxicity induced by doxorubicin was compared. Body weight and PB counts were monitored over a period of 30 days, after a single i.p. administration of the drug. Both genotypes exhibited a small drop in body weight, no change in red blood cell counts, and an increased number of monocytes and granulocytes after treatment (Supplemental Fig. 1 ), pointing to a slight trend for increased myelopoiesis, which was particularly evident for STAT1-deficient mice. However these effects did not reach statistical significance. B and T lymphocyte counts in the PB decreased transiently, indicative of a toxic effect on the lymphoid compartment ( Fig. 1 ; Days 3 and 7 after treatment). No significant differences between STAT1 WT and STAT KO mice were observed in the extent of this inhibitory effect. Thus, other than the reported findings on a facilitating role of STAT1 in promoting the proapoptotic effect of doxorubicin in tumor cell lines [3] , the in vivo effect of this drug on lymphocytes was not enhanced by STAT1. However, STAT1-deficient mice were impaired significantly in the capability to restore their B lymphocyte population in the PB, as noted in the recovery phase, up to 30 days after drug administration (Fig. 1A, upper) . The investigations on the effect of doxorubicin were extended to thymus (Fig. 2) , BM (Fig. 2) , and spleen (Fig. 3A) . A strong, suppressive effect of doxorubicin on the total cellularity of thymus and spleen and on undifferentiated lymphocyte precursors was observed at Days 3 and 7. Recovery from this suppression was visible in STAT1-proficient mice on Day 16 in spleen and BM, and on Day 30 in the thymus. By contrast, in STAT1-deficient mice, cellularity and abundance of lymphocyte precursors remained almost unchanged between Days 3 and 30 ( Figs. 2  and 3A) , indicating that the impaired recovery rate of B cells in the PB could be the consequence of impaired recovery of precursor cells. The results point to a defect in the repopulation of the lymphocyte compartment in the BM caused by STAT1 deficiency, which subsequently leads to an impaired replenishment of the lymphocyte population in the peripheral lymphatic organs. An impaired B cell repopulation of spleens from STAT1 KO mice 30 days after treatment with doxorubicin was also evident when immunofluorescence staining for CD19 and CD3 was performed (Fig. 3B ). Significantly smaller CD19 ϩ areas and a lower number of splenic nodules compared with their WT counterparts were found (Supplemental Fig. 2 ). Doxorubicintreated KO mice also exhibited less-organized, more-diffuse T cell areas within splenic nodules (Fig. 3B) .
The significant lower levels of T cell precursors of STAT1-deficient mice in the recovery phase and the failure to form an organized splenic T cell zone did not result in a decreased replenishment of the T cell pool in the PB (Fig. 1A,  lower) . A possible explanation for this effect is the longer half-life of mature T cells, as well as the lower susceptibility of STAT1-deficient, mature T cells but not B cells to apoptosis [21] . The latter may compensate for the reduced supply with T cell precursors from the BM and may also account for the increased CD4 ϩ and CD8 ϩ T lymphocyte counts in the PB of STAT1 KO mice under steady-state conditions ( Table 1) (Fig. 4 and Table 2 ) and spleen (Fig. 3A, Table 2 , and Supplemental Fig. 2A ). This was evident for the population of MPPs, and most pronounced for CLPs, with a population of only 34% of the size of STAT1-proficient mice (Fig. 4A) . Markers for these lymphocyte progenitor cells include the Sca-1, which has been described to be expressed by stem cells in a STAT1-dependent fashion [22] . As we cannot exclude that Sca-1 Ϫ cells may also be part of these progenitor cell populations and to correct for a potential underestimation of the size of these populations in STAT1-deficient mice, an analysis was also performed without the Sca-1 marker (Fig. 4B) . By this type of analysis, the decrease in the size of the CLP population observed in STAT1 KO mice remained significant, albeit less pronounced. A potential caveat for the significance of the cell numbers obtained without using Sca-1 is the expected, impaired differentiation capacity of Sca-1 Ϫ cells, as revealed by the HSC and progenitor defects observed in Sca-1 null mice [23] . Taken together, the results suggest an early defect in the development of hematopoietic cells, which leads to a reduced abundance of early precursors along the B cell lineage. Under steady-state conditions, the paucity of precursors did not lead to a decreased abundance of mature B cells in the PB (Table  1 and Fig. 1A ) but appears to be responsible for the lower rate of replenishment of the B cell pool after doxorubicin-induced BM toxicity. A lowered capacity of STAT1 null BM cells to re- Total numbers of hematopoietic cells from 5-to 6-week-old animals were calculated by counting single-cell suspensions derived from the indicated organs and tissues that were subsequently analyzed by flow cytometry after staining for cell-surface markers: total B cells (B220
, and monocytes (CD115 ϩ ). Numbers represent the mean Ϯ sem obtained from five to 10 STAT1 WT and five to seven STAT1 KO mice.
a P Ͻ 0.05 compared with WT mice; b P Ͻ 0.01 compared with WT mice.
populate the BM and peripheral organs was also observed in competitive BM transplantation experiments of lethally irradiated hosts (Fig. 5A) . There, a significantly decreased efficiency of donor engraftment provided evidence for a cell-autonomous defect of STAT1-deficient BM precursors. The defect was not selective for the lymphoid lineage but also led to a competitive disadvantage in the engraftment within the population of granulocytes and monocytes (Fig. 5B) .
Selective defect in the expansion along the lymphoid lineage
Interestingly, despite the poor myelocyte engraftment capacity of BM derived from STAT1 KO mice, STAT1 deficiency did not lead to a smaller size of the compartments of CMPs and GMP/MEPs ( Fig. 4D and E) under noncompetitive conditions. This is in agreement with normal or even higher counts of monocytes and granulocytes in BM and PB under steady-state conditions, as well as in response to doxorubicin-induced BM toxicity (Table 2 and Supplemental Fig. 1B) .
To verify the selective defect in the expansion of the lymphoid lineage under noncompetitive conditions, the capacity of BM cells to form pre-B cell, granulocyte, and monocyte colonies was compared in vitro with MethoCult colony-forming assays. An equal number of BM cells derived from STAT1-proficient or -deficient mice were used in these assays. As shown in Fig. 6A , the number of pre-B cell colonies formed was decreased to 25% with STAT1 null BM, whereas the number of granulocyte and monocyte colonies did not change (Fig. 6B) . The similar numbers of myeloid colonies in mice of both genotypes are in agreement with the similar numbers of the respective precursors in the BM and provide further evidence for a normal expansion of the myeloid lineage in STAT1-deficient mice under steady-state conditions.
As the differences in the numbers of pre-B cell colonies between STAT1-deficient and -proficient mice are similar to the differences in the numbers of CLP precursors in the BM (compare Figs. 4A with 6A) , the reduced number of colonies obtained with STAT1 null BM was considered to be the consequence of a reduced number of these precursors rather than a subsequent differentiation defect in the formation of pre-B cells. In accordance with this notion, no STAT1-dependent differences in the formation of pre-B colonies were observed when the MethoCult experiment was performed with sorted pro-B cells purified from BM (Fig. 6A) . Similarly, IL-7-induced in vitro differentiation of B cells from the BM cells was not impaired in the absence of STAT1: when equal amounts of BM-derived B220
ϩ -sorted cells of each genotype were used in these assays, the efficiency of differentiation to pro-B, pre-B, and immature B cells (Fig. 7A) , as well as the percentage of proliferating cells in these cultures, was similar (Fig. 7B-D) . Furthermore, the formation of a polyclonal B cell repertoire with different rearrangements of the Ig heavy chain locus, as determined by spectratyping, was independent of the STAT1 phenotype (Supplemental Fig. 3 ), indicating that this differentiation step, occurring in pre-B cells and preceding the development of immature B cells [16] , is intact.
Transcriptional response to IL-7 remains unaltered in STAT1-deficient B lymphocyte precursors
STAT1 has been demonstrated to be involved at the very beginning of hematopoiesis in mediating the activation of dormant HSCs in response to IFNs [22, 24] . Later, STAT1 is also required for the IFN-␥-induced differentiation of mature B lymphocytes [25] . A specific requirement for STAT1 in early stages of development, specific for the B-lymphocyte lineage, has not been described so far. There have been reports that IL-7, the major cytokine involved in the differentiation of B cells in the BM [26] , is able to activate, in addition to STAT5 [27] , STAT1 in T lymphocytes [25] and a BCL cell line [28] , raising the possibility of a contribution of STAT1 to IL-7-dependent early B cell development. A potential link between IL-7 and STAT3 activation was also described [28, 29] . We therefore examined the activation of STAT5, STAT3, and STAT1 in response to IL-7 and the effect of STAT1 deficiency on genes regulated by IL-7 in B cells differentiated in vitro from BM cells. As a control IFN-␥ was used to activate STAT1. In differentiated B cells derived from WT mice, STAT1 Y701 phosphorylation was detectable in the absence of cytokine stimulation, and this basal level was increased by IFN-␥ but not by IL-7 (Fig. 8A) . Furthermore, expression of the STAT1 target genes IRF-1, CXCL10, Mx1, IRF-8, and SOCS1, as well as the IRF-8 target gene BCL6 [30] , was increased by IFN-␥ but not by IL-7 (Fig. 8B) . As expected, STAT1-deficient cells did not exhibit activation of these genes by IFN-␥. By contrast, STAT5 tyrosine phosphorylation and expression of the STAT5 target genes CIS, SOCS2, and SOCS3 were increased significantly in response to IL-7 but not to IFN-␥, both in STAT1 WT and STAT1 KO cells (Fig. 8) . STAT3 tyrosine phosphorylation was induced only by IFN-␥ in STAT1 WT and to a smaller extent, in STAT1 KO cells (Fig. 8A) . The results support the notion of a selective activation of STAT5 by IL-7 and of STAT1 by IFN-␥ in developing B lymphocytes and the STAT1 and STAT3 independence of IL-7 signaling in early lymphocyte development.
Analysis of regulators of early B cell development reveals a decreased expression of the Sca-1 in STAT1-deficient B-lymphocyte precursors
The transcription factors PU.1, EBF1, Pax5, Ikaros, Aiolos, and IRF-8 have been defined as important regulators of early B cell development in the BM [31, 32] . Furthermore, Sca-1 has been described to be not only a marker for stem cells but also involved in the regulation of stem-cell self-renewing and development of committed progenitor cells [23, 33] . Comparison of the RNA expression of these genes in STAT1-proficient and -deficient pro-B cells revealed a significant dropdown of Sca-1 in STAT1 KO cells, whereas no change in the expression of the other investigated genes was observed (Fig. 9) . Thus, the transcription of Sca-1 is dependent on STAT1, not only in HSCs [22] but also in pro-B cells.
DISCUSSION
As an IFN-inducible transcription factor, STAT1 plays a central role in the transcription of genes required for efficient innate and adaptive immune functions [1, 5] . STAT1 is also implicated in the development of hematopoietic cells. It exerts a supporting function in erythropoiesis [34] and promotes megakaryopoiesis [35] . Furthermore, the balance between STAT1 and STAT5 has been suggested to be important to direct the phenotype of myeloproliferative neoplasms of the erythroid lineage, with higher STAT1 levels favoring essential thrombocythemia [36] . In response to inflammation with increased turnover of cells in the periphery, activation of HSCs from their dormant state is promoted by IFNs and STAT1, leading to enhanced hematopoiesis to compensate for cell loss [22, 37, 38] . In this study, we document a requirement for STAT1 in the recovery from doxorubicin-induced BM toxicity. Decreased abundance of CLPs (Fig. 4A and B and Table 2 ) and general reduced competitive fitness of BM cells derived from STAT1-deficient mice to repopulate the hematopoietic system (Fig. 5 ) are likely to contribute to this effect. STAT1 deficiency predominantly affected the lymphoid lineage, in particular, B cells, as evident by (1) the delayed replenishment of the pool of mature B cells but not T cells in the periphery after doxorubicin-induced BM insult (Fig. 1) , (2) the selective effect on CLP but not GMP/MEP abundance under steady-state conditions (Fig. 4) , and (3) the reduced formation of pre-B cell colonies but not of granulocyte and monocyte colonies by BM cells in vitro (Fig. 6) . The mechanistic basis for the differential effect of STAT1 on the myeloid versus lymphoid compartment remains to be elucidated. It could be the consequence of an impact of STAT1 on the establishment of the transcription factor network influencing B cell specification and the commitment to the myeloid or lymphoid lineage. However, analysis of the expression levels of important transcription factors involved in this process, such as IRF-8 [39] , PU.1, Pax5, Ikaros, Aiolos, and EBF1 (Fig. 9) , did not provide evidence that this is the case. A protein differentially expressed with respect to STAT1 status, which might be relevant to explain the B-lineage-specific effect, is Sca-1: the expression of this gene does not only serve as a marker for HSCs and MPPs but also for CLPs, whereas myeloid progenitors are defined as a Sca-1 Ϫ population. A functional role of Sca-1 in hematopoiesis was demonstrated by HSC and progenitor defects of Sca-1-deficient mice [23, 33] . Its specific expression in lymphoid progenitors and the substantial lower expression in CLP and pro-B cells of STAT1-deficient mice (Figs. 4B and 9) are in agreement with a potential, additional function in B cell lineage commitment. Reduced expression of this protein may thus serve as a contributing defect for the compromised expansion along the lymphoid lineage in STAT1-deficient mice.
The clonal diversity of immature B cells derived from the BM did not depend on STAT1, indicating that the reduced size of the immature B cell compartment in STAT1-KO mice was not the consequence of reduced survival and loss of pre-B cells with productive V H -DJ H gene rearrangements, as it is observed with BCL6-deficient mice [16] , but was rather a result of limited supply with early lymphoid precursors.
An important determinant in directing lineage specification and differentiation during hematopoiesis is the differential activation of the STAT family members by cytokine receptors. In lymphocyte development, STAT5 and its activation via the IL-7R is the most critical event and has been demonstrated to control cell survival and Ig gene recombination during pro-B cell development [27] . There is also a report documenting a nonredundant function of STAT3 in early B cell development, as mice with STAT3-deficient BM progenitors are hyporesponsive to IL-7 and contain fewer mature B cells, as wells as reduced numbers of pro-B and pre-B cells [29] . By contrast, the observed dependence of early lymphocyte development on STAT1, reported in our present study, appeared not to be mediated by IL-7R, as the differentiation and proliferation of BM cells upon IL-7 proceeded at the same rate in the absence and presence of STAT1. Furthermore, and in contrast to results obtained with cell lines [28] , triggering of the IL-7R by IL-7 only activated STAT5 but not STAT3 and STAT1 in BM-derived B lymphocytes.
As expected, STAT1 deficiency resulted in a profound inhibition of the IFN-␥ response of BM-derived B lymphocytes (Fig. 8) . IFNs have been shown to dampen lymphocyte differentiation driven by IL-7 [40, 41] , and IFN-␥ was demonstrated to promote the development of Lin Ϫ Sca-1 ϩ c-Kit ϩ hematopoietic precursors cells toward myeloid lineages rather than toward lymphoid lineages [42] . Furthermore, abnormal secretion of IFN-␥ by stroma cells in the BM was reported to be a consequence of T cell protein tyrosine phosphatase deficiency, and this has been implicated to be responsible for high constitutive STAT1 levels in pre-B cells and impairment of lymphopoiesis at a step between pre-B cells and immature B cells [43] . However, the action of IFNs is strongly dependent on their concentration and different and even opposing effects, depending on the duration of the engagement of their receptors with the ligands have been described [44] . Thus, a positive STAT1-mediated effect of type I or type II IFNs on early lymphocyte development cannot be ruled out as well. Concentration and duration of signaling also appear to be relevant for the effects of IFNs on HSCs, which can result in their activation and proliferation, as well as exhaustion after chronic treatment [38] .
Evolving evidence documents the contribution of lesions in hematopoietic precursors to lymphoid transformation, including alterations that modify proliferation, apoptosis, or differentiation at early stages of lymphopoiesis [45] . On this line, alterations in STAT1 and STAT1-dependent signaling might contribute to lymphomagenesis. In particular, loss of STAT1 function might predispose to lymphoma development, in analogy to the antioncogenic function of STAT1 in other tissues: loss of STAT1 was shown to enhance the frequency of spontaneous development of mammary tumors [46, 47] and promoted the formation of teratomas originating from the ovary [48] . Furthermore, STAT1 deficiency lead to a shorter latency of appearance of mammary tumors driven by overexpression of erbB2/neu [9, 18, 49] . On the other hand, activation of STAT1 signaling as a result of increased secretion of IFN-␥ by BM stroma has been shown to promote apoptosis of pre-B leukemic cells, and it was suggested that this could serve as a potential therapeutic approach for selected forms of B cell leukemia [43] .
In summary, the studies presented here identify a nonredundant role of STAT1 in early lymphocyte development, upstream of the differentiation of pro-B cells at two developmental stages: (1) it confers a competitive advantage in the repopulation of the BM in a cell-autonomous fashion, and (2) it is required specifically for the expansion along the lymphoid lineage. The second effect became relevant for the restoration of homeostasis under conditions of increased demands of lymphopoiesis, namely in the recovery phase from doxorubicin-induced BM toxicity. Thus, STAT1 not only modulates the response to infections and genotoxic stress by inducing genes required for the protection of the host and for the elimination of pathogens but also, is involved in tissue homeostasis by facilitating the supply of lymphoid precursors to replenish the pool of mature lymphocytes after BM toxicity. More specifically, our data imply an important general role of STAT1 in the regeneration of the BM and expansion of the B-lymphoid lineage after insults elicited by genotoxic chemotherapeutic agents and thus, indicate a requirement for STAT1 in preventing longlasting immunosuppression after chemotherapy. AUTHORSHIP S.D., N.P., P.T., A.V., and W.D. contributed to study design and interpretation of data. S.D., N.P., P.T., R.S., W.P., and E.O. performed experiments. W.D. wrote the paper. 
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ϩ IgM Ϫ cells and mRNA expression levels of the indicated genes determined by RT-PCR analysis. Expression was normalized to the expression of TBP and is shown as the mean Ϯ sem from three experiments.
